PA8597201A1 - Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos - Google Patents

Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos

Info

Publication number
PA8597201A1
PA8597201A1 PA20048597201A PA8597201A PA8597201A1 PA 8597201 A1 PA8597201 A1 PA 8597201A1 PA 20048597201 A PA20048597201 A PA 20048597201A PA 8597201 A PA8597201 A PA 8597201A PA 8597201 A1 PA8597201 A1 PA 8597201A1
Authority
PA
Panama
Prior art keywords
disorders
compounds
drinks
nachrs
arilvinilazacicloalcano
Prior art date
Application number
PA20048597201A
Other languages
English (en)
Inventor
Jefrey Daniel Schmitt
Gary Maurice Dull
Arielle Genevois-Barella
Marc Capet
Michel Cheve
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PA8597201A1 publication Critical patent/PA8597201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REVELAN COMPUESTOS VINILAZACICLOALCANO NOVEDOSOS DE LA FORMULA (I). LOS COMPUESTOS SON LIGANDOS DE DIVERSOS NACHRS. LOS COMPUESTOS Y SUS SALES FARMACEUTICAMENTE ACEPTABLES PUEDEN UTILIZARSE PARA PREPARAR COMPOSICIONES FARMACEUTICAS Y/O MEDICAMENTOS PARA PREVENIR O TRATAR TRASTORNOS ASOCIADOS CON LA DISFUNCION DE NACHRS, ESPECIALMENTE DENTRO DEL SISTEMA NERVIOSO CENTRAL O EL SISTEMA GASTROINTESTINAL. EJEMPLOS DE TIPOS DE TRASTORNOS QUE PUEDEN TRATARSE INCLUYEN TRASTORNOS NEURODEGENERATIVOS, QUE INCLUYEN TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL TALES COMO ENFERMEDAD DE ALZHEIMER, TRASTORNOS COGNITIVOS, TRASTORNOS MOTORES TALES COMO ENFERMEDAD DE PARKINSON, ADICCION A LAS DROGAS, TRASTORNOS DE CONDUCTA Y TRASTORNOS INFLAMATORIOS DENTRO DEL SISTEMA GASTROINTESTINAL. LOS COMPUESTOS TAMBIEN PUEDEN SERVIR COMO ANALGESICOS EN EL TRATAMIENTO DEL DOLOR AGUDO, CRONICO O RECURRENTE.
PA20048597201A 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos PA8597201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
PA8597201A1 true PA8597201A1 (es) 2004-09-28

Family

ID=32926772

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048597201A PA8597201A1 (es) 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos

Country Status (32)

Country Link
US (8) US7098331B2 (es)
EP (3) EP2085395B1 (es)
JP (3) JP4663627B2 (es)
KR (4) KR20120014236A (es)
CN (3) CN101550132B (es)
AR (3) AR043469A1 (es)
AT (3) ATE496046T1 (es)
AU (3) AU2004217903B2 (es)
BR (1) BRPI0409576A (es)
CA (1) CA2516514C (es)
CL (1) CL2004000452A1 (es)
CY (2) CY1110391T1 (es)
DE (2) DE602004013553D1 (es)
DK (2) DK1601670T3 (es)
EA (3) EA014714B1 (es)
ES (3) ES2309507T3 (es)
GT (1) GT200400033A (es)
HK (3) HK1084949A1 (es)
IL (3) IL170155A (es)
JO (1) JO2488B1 (es)
MX (1) MXPA05009386A (es)
NO (3) NO331920B1 (es)
NZ (1) NZ541795A (es)
PA (1) PA8597201A1 (es)
PE (1) PE20040930A1 (es)
PL (5) PL394600A1 (es)
PT (2) PT2085395E (es)
SI (2) SI1601670T1 (es)
TW (3) TWI377204B (es)
UY (1) UY28218A1 (es)
WO (1) WO2004078752A1 (es)
ZA (1) ZA200506790B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2647373A1 (en) * 2008-05-12 2013-10-09 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine.
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
EP3279195B1 (en) * 2008-12-01 2020-07-01 Oyster Point Pharma, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CN102802630A (zh) * 2009-06-17 2012-11-28 塔加西普特公司 通过神经元烟碱受体配体逆转左旋多巴诱导的运动障碍
JP2013512922A (ja) 2009-12-07 2013-04-18 ターガセプト，インコーポレイテッド 神経型ニコチン性アセチルコリン受容体リガンドとしての３，６−ジアザビシクロ［３．１．１］ヘプタン
JP2013522201A (ja) * 2010-03-11 2013-06-13 ターガセプト，インコーポレイテッド 便秘のためのアリールビニルアザシクロアルカン化合物
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
BR112018070497A2 (pt) 2016-04-07 2019-01-29 Oyster Point Pharma Inc métodos e formulações farmacêuticas para tratamento de condições oculares
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
TW202019417A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
HU226859B1 (en) 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
AU5326100A (en) 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2381252A1 (en) 1999-09-14 2001-03-22 Abbott Laboratories 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
AU780492B2 (en) 1999-11-01 2005-03-24 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
KR20090021227A (ko) 2009-02-27
ES2385941T3 (es) 2012-08-03
EP1947100A1 (en) 2008-07-23
DK1601670T3 (da) 2008-08-25
CA2516514C (en) 2012-02-07
PL216979B1 (pl) 2014-06-30
AU2008258187B2 (en) 2010-08-05
CA2516514A1 (en) 2004-09-16
KR20060006006A (ko) 2006-01-18
NZ541795A (en) 2008-03-28
EP1601670A1 (en) 2005-12-07
JP2009292825A (ja) 2009-12-17
AR070569A2 (es) 2010-04-21
NO20054120D0 (no) 2005-09-05
EP2085395A1 (en) 2009-08-05
DE602004031165D1 (de) 2011-03-03
ATE517893T1 (de) 2011-08-15
EA200801764A1 (ru) 2008-12-30
IL170155A (en) 2013-08-29
US20100010042A1 (en) 2010-01-14
ES2389106T3 (es) 2012-10-23
US20040176348A1 (en) 2004-09-09
US8633222B2 (en) 2014-01-21
PT1601670E (pt) 2008-07-11
TWI377204B (en) 2012-11-21
DE602004013553D1 (de) 2008-06-19
EA019240B1 (ru) 2014-02-28
IL197889A (en) 2013-03-24
SI2085395T1 (sl) 2011-05-31
KR100953150B1 (ko) 2010-04-19
KR101018083B1 (ko) 2011-03-02
CY1111615T1 (el) 2015-10-07
PL394600A1 (pl) 2011-07-18
EA010870B1 (ru) 2008-12-30
KR20120014236A (ko) 2012-02-16
AU2004217903A1 (en) 2004-09-16
NO20091888L (no) 2005-10-03
ATE496046T1 (de) 2011-02-15
HK1116800A1 (en) 2009-01-02
JP2010001296A (ja) 2010-01-07
GT200400033A (es) 2005-05-29
BRPI0409576A (pt) 2006-04-18
AU2008258188B2 (en) 2011-02-24
CL2004000452A1 (es) 2005-05-20
US20140107164A1 (en) 2014-04-17
ZA200506790B (en) 2006-05-31
PL1601670T3 (pl) 2008-10-31
AR043469A1 (es) 2005-07-27
JO2488B1 (en) 2009-10-05
AU2008258188A1 (en) 2009-01-15
HK1130254A1 (en) 2009-12-24
DK2085395T3 (da) 2011-04-18
PT2085395E (pt) 2011-04-20
US7714001B2 (en) 2010-05-11
EP1601670B1 (en) 2008-05-07
WO2004078752A1 (en) 2004-09-16
PL378415A1 (pl) 2006-04-03
CN101550132B (zh) 2012-03-28
MXPA05009386A (es) 2005-11-04
EA200900706A1 (ru) 2009-10-30
JP4663627B2 (ja) 2011-04-06
ES2309507T3 (es) 2008-12-16
TW200927745A (en) 2009-07-01
EA014714B1 (ru) 2011-02-28
US7098331B2 (en) 2006-08-29
PL215059B1 (pl) 2013-10-31
AR070570A2 (es) 2010-04-21
US20150164894A1 (en) 2015-06-18
TW200505909A (en) 2005-02-16
PL394604A1 (pl) 2011-07-18
EP2085395B1 (en) 2011-01-19
US8063068B2 (en) 2011-11-22
US20080293778A1 (en) 2008-11-27
US8067443B2 (en) 2011-11-29
AU2004217903B2 (en) 2010-03-04
HK1084949A1 (en) 2006-08-11
JP2006519868A (ja) 2006-08-31
SI1601670T1 (sl) 2008-10-31
UY28218A1 (es) 2005-06-30
TW200927746A (en) 2009-07-01
CN101550132A (zh) 2009-10-07
CN101255155A (zh) 2008-09-03
NO332293B1 (no) 2012-08-20
AU2008258187A1 (en) 2009-01-15
EP1947100B1 (en) 2011-07-27
CN100526308C (zh) 2009-08-12
CY1110391T1 (el) 2015-04-29
NO20092231L (no) 2005-10-03
PL2085395T3 (pl) 2011-05-31
KR20090021228A (ko) 2009-02-27
NO331920B1 (no) 2012-04-30
ATE394394T1 (de) 2008-05-15
EA200501425A1 (ru) 2006-02-24
US20100267776A1 (en) 2010-10-21
NO20054120L (no) 2005-10-03
KR101185541B1 (ko) 2012-09-24
JP5537084B2 (ja) 2014-07-02
PE20040930A1 (es) 2005-02-18
US20060094732A1 (en) 2006-05-04
TWI339662B (en) 2011-04-01
CN1756754A (zh) 2006-04-05
IL197890A (en) 2013-11-28
US20110152293A1 (en) 2011-06-23
JP5537085B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
PA8597201A1 (es) Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de ellos
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
AR033485A1 (es) Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
CL2008000647A1 (es) Compuestos derivados de indazol; composicion farmaceutica; yuso en el tratamiento de enfermedades tales como dolor, trastornos inflamatorios cronicos, trastornos del snc, entre otros.
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CL2008002809A1 (es) Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.
DE602004020494D1 (de) Analgetische verbindungen, deren synthese und pharmazeutische zusammensetzungen, die diese enthalten
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
MX2018003685A (es) Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
UY29741A1 (es) Sales de 1,5- diaril pirazol-3-carboxamidas, procesos de preparación, composeciones farmacéuticas que las contienen, aplicaciones y métodos de uso.
PE20011049A1 (es) Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
CL2008003232A1 (es) Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
Youssef et al. Evaluation of chronic statin treatment on sepsis outcome in ICU
RU2014106661A (ru) Лекарственное средство на основе левомилнаципрана, предназначенное для функциональной реабилитации после острых неврологических нарушений